|
2025
|
Invention
|
Combination of an immunocytokine comprising targeted il2 and a jak inhibitor. The invention relat... |
|
|
Invention
|
Methods for treating melanoma. The disclosure relates to methods for treating melanoma with combi... |
|
2024
|
G/S
|
Pharmaceutical, biopharmaceutical and veterinary preparations for the treatment of cancers; pharm... |
|
|
G/S
|
Pharmaceutical, biopharmaceutical, and veterinary preparations for the treatment of cancer, parti... |
|
|
G/S
|
Pharmaceutical, biopharmaceutical, and veterinary
preparations for the treatment of cancer, part... |
|
|
Invention
|
Anti-cea antibodies. Anti-CEA Antibodies The application relates to the diagnosis and treatment o... |
|
2023
|
Invention
|
Tnf-alpha immunoconjugate therapy for the treatment of brain tumors. The present invention relate... |
|
|
Invention
|
Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancer.
The application re... |
|
|
Invention
|
Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancer. The application rel... |
|
|
Invention
|
Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancer |
|
|
Invention
|
Antibody binding to pd1. The present invention relates to an antibody binding to PD-1 (Fig 8). |
|
|
Invention
|
Anti-cd28 antibodies.
The application relates to the diagnosis and treatment of diseases, includ... |
|
|
Invention
|
Anti-cd28 antibodies. The application relates to the diagnosis and treatment of diseases, includi... |
|
|
Invention
|
Il2 immunoconjuqate preparation.
The application relates to a preparation, in particular a pharm... |
|
|
Invention
|
Il2 immunoconjuqate preparation. The application relates to a preparation, in particular a pharma... |
|
|
Invention
|
Tnfalpha immunoconjugate preparation.
The application relates to a preparation, in particular a ... |
|
|
Invention
|
Tnf.alpha. immunoconjugate preparation. The application relates to a preparation, in particular a... |
|
|
Invention
|
Tnfα immunoconjugate preparation. The application relates to a preparation, in particular a pharm... |
|
|
Invention
|
Anti-ed-a antibodies for the treatment of pulmonary hypertension. The present application relates... |
|
|
Invention
|
Combination of an immunocytokine comprising il-12 and a kinase inhibitor.
The invention relates ... |
|
|
Invention
|
Combination of an immunocytokine comprising il-12 and a kinase inhibitor. The invention relates t... |
|
2022
|
Invention
|
Antibody compositions. This invention relates to stable formulations that can be prepared to high... |
|
|
Invention
|
Anti-fibroblast activation protein antibodies.
The application relates to the diagnosis and trea... |
|
|
Invention
|
Anti-fibroblast activation protein antibodies. The application relates to the diagnosis and treat... |
|
|
Invention
|
Improved interferon-gamma mutant. The present invention relates to conjugates comprising a mutant... |
|
|
G/S
|
Biopharmaceutical preparations for the treatment of cancers; antibodies and antibody derivatives ... |
|
|
G/S
|
Pharmaceutical, biopharmaceutical and veterinary
preparations for the treatment of cancers, incl... |
|
2021
|
Invention
|
Il2 and tnf mutant immunoconjugates.
The present application relates to conjugates comprising in... |
|
|
Invention
|
Treatment of pulmonary hypertension.
The present application relates to the treatment of pulmona... |
|
|
Invention
|
Treatment of pulmonary hypertension. The present application relates to the treatment of pulmonar... |
|
|
G/S
|
Pharmaceutical, biopharmaceutical and veterinary preparations for the treatment of cancers, inclu... |
|
|
Invention
|
Tnfα immunoconjugate therapy for the treatment of brain tumors. The present invention relates to ... |
|
|
Invention
|
Tnf.alpha. immunoconjugate therapy for the treatment of brain tumors. The present invention relat... |
|
|
Invention
|
Dosage units and regimen, uses, methods or formulations of compositions comprising a recombinant ... |
|
2020
|
Invention
|
Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sus... |
|
2019
|
Invention
|
Il2 immunoconjugates. The present application relates to a conjugate for targeting an agent, such... |
|
|
Invention
|
Antigen associated with rheumatoid arthritis.
The invention relates to a binding member that bin... |
|
|
Invention
|
Il2 and tnf immunoconjugates. The present application relates to conjugates comprising interleuki... |
|
|
Invention
|
Cancer treatment using immunoconjugates and immune check-point inhibitors. This invention relates... |
|
|
Invention
|
Edb targeting il-12 compositions. The present invention relates to compositions comprising an int... |
|
|
Invention
|
Edb targeting il-12 compositions. The present invention relates to compositions comprising an IL-... |
|
2018
|
Invention
|
Antibodies to tumour antigens. The present application relates to specific binding members that b... |
|
|
Invention
|
Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins. The application rel... |
|
|
Invention
|
Immunocytokine combination therapy.
This invention relates to methods and compositions, in a com... |
|
|
Invention
|
Immunoconjugates with optimized linkers and orientation.
The present invention relates to fusion... |
|
2017
|
Invention
|
Immunocytokines with progressive activation mechanism.
The present invention relates to a combin... |
|
|
Invention
|
Il2 and tnf mutant immunoconjugates. The present application relates to conjugates comprising int... |
|
|
Invention
|
Novel interleukin 4 immunoconjugates.
This invention relates to an immunoconjugate comprising in... |
|
|
Invention
|
Intestinal antigens for pharmacodelivery applications.
The present invention relates to the trea... |
